Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis

PHASE2CompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Herpes Labialis
Interventions
DRUG

NB-001

Trial Locations (28)

19438

Lederach Family Medicine, Harleysville

24073

New River Valley Research Institute, Christiansburg

27612

Wake Research Associates, LLM, Raleigh

29464

Coastal Carolina Research Center, Mt. Pleasant

29902

Okatie Research Center, LLC, Beaufort

33765

Clinical Research of West Florida, Clearwater

33916

Clinical Physiology Associates, Fort Myers

34652

Suncoast Clinical Research, New Port Richey

35801

Medical Affiliated Research Center, Inc., Huntsville

40217

DermResearch, PLCC, Louisville

48038

MI Center for Skin Care Research, Clinton Township

53209

Advanced Healthcare, Milwaukee

75230

Dermatology Treatment & Research Center, Dallas

75234

Research Across America, Dallas

77566

R/D Clinical Research, Inc, Lake Jackson

77802

J&S Studies Inc., Bryan

78705

Benchmark Research, Austin

78759

DermResearch Inc., Austin

80033

Front Range Clinical Research, Wheat Ridge

83704

Advanced Clinical Research, Inc., Boise

84088

South Valley Dermatology Center, West Jordan

91361

Westlake Medical Research, Westlake Village

92801

Advanced Clinical Research Institute, Anaheim

97210

Westover Heights Clinic, Portland

98801

Wenatchee Valley Medical Center, Wenatchee

06511

The Savin Center, PC, New Haven

87106-5239

Academic Dermatology Associates, Albuquerque

02888

Omega Medical Research, Warwick

Sponsors
All Listed Sponsors
lead

NanoBio Corporation

INDUSTRY